Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
1.
Zhonghua Yu Fang Yi Xue Za Zhi ; 56(4): 464-467, 2022 Apr 06.
Artigo em Chinês | MEDLINE | ID: mdl-35488544

RESUMO

Objective: To evaluate the safety and immunogenicity of hepatitis E vaccine(HEV)in Maintenance hemodialysis(MHD)patients. Methods: Based on an open-labeled controlled trial, from May 2016 to March 2018, 35 eligible MHD patients were recruited in the Hemodialysis Center of Zhongshan Hospital Affiliated to Xiamen University as the experimental group, and 70 MHD patients with matched age, gender and underlying diseases as the control group. The experimental group received HEV at 0, 1 and 6 months according to the standard vaccination procedures, while the control group received routine diagnosis and treatment without vaccine and placebo injection to observe the safety and immunogenicity of the vaccine. The safety of vaccine in MHD population was evaluated by the incidence of adverse reactions/events in the experimental and control groups. The immunogenicity of HEV in MHD patients was evaluated by comparing the data from the phase Ⅲ clinical trial. Results: The overall incidence of adverse reactions/events was 17.1% (18/105), and there were no grade 3-4 adverse reactions/events related to vaccination. In the experimental group, the incidence of local adverse reactions/events was 20.0% (7/35), and the incidence of systemic adverse reactions/events was 17.1% (6/35).There was no significant difference in the incidence of systemic adverse reactions/events between the experimental group and the control group (P>0.05). There were 23 patients receiving 3 doses with the standard schedule. The positive rate of HEV-IgG antibody was 100% and the GMC was 14.47(95%CI:13.14-15.80) WU/ml, which showed no significant difference compared with the 46 patients in Phase Ⅲ clinical trial (t=-1.04, P>0.05). Conclusion: Recombinant HEV has good safety and immunogenicity in MHD patients.


Assuntos
Hepatite E , Vacinas contra Hepatite Viral , Ensaios Clínicos Fase III como Assunto , Feminino , Humanos , Imunogenicidade da Vacina , Imunoglobulina G , Masculino , Diálise Renal , Vacinas contra Hepatite Viral/efeitos adversos
2.
Climacteric ; 10(4): 306-13, 2007 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-17653957

RESUMO

OBJECTIVE: To assess the effects of three doses of continuously combined conjugated estrogens (CE) and medroxyprogesterone acetate (MPA) on bone turnover and cartilage degradation markers in early postmenopausal Asian women (mean age 53.6 years). METHODS: A total of 1028 women were randomly allocated to receive treatment with either 0.625/2.5, 0.45/1.5, or 0.3/1.5 mg CE/MPA for 6 months. End-points were the percent change from baseline in markers of bone resorption (alpha alpha CTX, beta beta CTX), bone formation (osteocalcin), and cartilage degradation (CTX-II). RESULTS: The 0.45/1.5 mg and the 0.625/2.5 mg doses elicited comparable responses as measured by the biomarkers. Women with high rates of bone or cartilage turnover at baseline responded with larger changes to the effects of CE/MPA. CONCLUSIONS: Lowering the commonly used dose of 0.625 mg CE + 2.5 mg MPA to 0.45 mg CE + 1.5 mg MPA does not significantly alter the inhibitory effect on bone and cartilage turnover in Asian women.


Assuntos
Remodelação Óssea/fisiologia , Cartilagem/fisiopatologia , Anticoncepcionais Orais Sintéticos/administração & dosagem , Estrogênios Conjugados (USP)/administração & dosagem , Estrogênios/administração & dosagem , Medroxiprogesterona/administração & dosagem , Adulto , Idoso , Biomarcadores/análise , Colágeno/urina , Colágeno Tipo I/urina , Relação Dose-Resposta a Droga , Método Duplo-Cego , Ensaio de Imunoadsorção Enzimática , Terapia de Reposição de Estrogênios , Feminino , Humanos , Isomerismo , Pessoa de Meia-Idade , Osteocalcina/sangue , Peptídeos/urina , Pós-Menopausa/fisiologia , Estudos Prospectivos
3.
Climacteric ; 9(2): 146-51, 2006 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-16698661

RESUMO

These Guidelines summarize the position of an Expert Panel on Menopause in Asian Women regarding the use of hormone replacement therapy (HRT) during the menopausal transition and thereafter. They are intended to aid gynecologists, family physicians and other health-care professionals in providing optimal care to menopausal Asian women who desire HRT.


Assuntos
Terapia de Reposição de Estrogênios/normas , Ginecologia/normas , Menopausa , Padrões de Prática Médica/normas , Ásia , Feminino , Humanos , Pessoa de Meia-Idade
4.
Climacteric ; 7(3): 312-8, 2004 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-15669556

RESUMO

OBJECTIVE: We investigated the effects of 2 months of treatment with topical estrogens on atrophic vaginitis and gynecological health in Asian women. STUDY DESIGN: Multicenter, open-label trial of 150 postmenopausal women age <70 years with atrophic vaginitis. Women applied conjugated equine estrogens (CEE) vaginal cream (0.625 mg/g) once daily on days 1-21 of two 28-day cycles. Changes in the vaginal maturation index (VMI) from baseline to days 21 (month 1) and 49 (month 2) were the primary outcome. Physiological changes were assessed by the Genital Health Clinical Examination (GHCE). RESULTS: The VMI was significantly improved (p < 0.001) from baseline at each assessment period. The significant improvement in GHCE from baseline after 1 month (p < 0.001) was maintained at 2 months. CONCLUSIONS: Vaginal treatment with CEE cream for 21 days of two consecutive 28-day cycles resulted in beneficial changes in the vaginal tissues and induced an overall genital health pattern more characteristic of the premenopausal state.


Assuntos
Terapia de Reposição de Estrogênios , Estrogênios Conjugados (USP)/administração & dosagem , Vaginite/tratamento farmacológico , Administração Cutânea , Adulto , Idoso , Povo Asiático , China , Feminino , Hong Kong , Humanos , Malásia , Pessoa de Meia-Idade , Filipinas , Pós-Menopausa , Índice de Gravidade de Doença , Singapura , Taiwan , Resultado do Tratamento , Vaginite/genética , Vaginite/patologia , Saúde da Mulher
5.
Radiat Prot Dosimetry ; 106(3): 257-62, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14690328

RESUMO

GNARD (Guangdong Nuclear Accident Real-time Decision support system) is a decision support system for off-site emergency management in the event of an accidental release from the nuclear power plants located in Guangdong province, China. The system is capable of calculating wind field, concentrations of radionuclide in environmental media and radiation doses. It can also estimate the size of the area where protective actions should be taken and provide other information about population distribution and emergency facilities available in the area. Furthermore, the system can simulate and evaluate the effectiveness of countermeasures assumed and calculate averted doses by protective actions. All of the results can be shown and analysed on the platform of a geographical information system (GIS).


Assuntos
Planejamento em Desastres , Reatores Nucleares , Centrais Elétricas , Liberação Nociva de Radioativos , China , Computadores , Bases de Dados como Assunto , Sistemas de Informação Geográfica , Humanos , Sistemas de Informação , Software
6.
Mol Psychiatry ; 8(7): 706-9, 2003 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-12874607

RESUMO

A number of studies have indicated that 8p22-p12 is likely to harbor schizophrenia susceptibility loci. In this region, the candidate gene of interest, neuregulin 1 (NRG1), may play a role in the pathogenesis of schizophrenia. Then in the present study, we performed the linkage disequilibrium to determine the association between three genetic variants (SNPs: rs3924999, rs2954041, SNP8NRG221533) on NRG1 gene and schizophrenia in 246 Chinese Han schizophrenic family trios using PCR-based restriction fragment length polymorphism method and denaturing high-performance liquid chromatography. The transmission disequilibrium test analysis for each variant showed a significant difference between two transmitted alleles even after Bonferroni correction (rs3924999, P=0.007752; rs2954041, P=0.0009309; SNP8NRG221533, P=0.012606). The global chi(2) test for haplotype transmission also revealed a strong association (chi(2)=46.068, df=7, P&<0.000001). Our results suggest that the NRG1 gene may play a role in conferring susceptibility to the disease.


Assuntos
Cromossomos Humanos Par 8/genética , Neuregulina-1/genética , Esquizofrenia/genética , Adulto , Alelos , Povo Asiático/genética , China/epidemiologia , Cromatografia Líquida de Alta Pressão , Mapeamento Cromossômico , Etnicidade/genética , Feminino , Frequência do Gene , Predisposição Genética para Doença , Genótipo , Haplótipos/genética , Humanos , Desequilíbrio de Ligação , Masculino , Neuregulina-1/fisiologia , Reação em Cadeia da Polimerase , Polimorfismo Genético , Polimorfismo de Fragmento de Restrição , Polimorfismo de Nucleotídeo Único , Esquizofrenia/epidemiologia
7.
Avian Dis ; 42(1): 186-9, 1998.
Artigo em Inglês | MEDLINE | ID: mdl-9533099

RESUMO

Through determining the serum and egg yolk antibody titers in immunized laying hens to Pasteurella multocida regularly, the growth-decline trend of the egg yolk antibody levels was found to be similar to that of the serum antibody levels (r = 0.94), but the growth and decline of the egg yolk antibody seemed to be delayed 3-6 days compared with that of the serum antibody, and the egg yolk antibody titers were generally lower than those of the serum antibody (P < 0.01). Serum and egg yolk antibody levels declined 3 and 6 days, respectively, after booster immunizations. The higher the antibody levels were before booster immunization, the more they declined.


Assuntos
Vacinas Bacterianas , Gema de Ovo/imunologia , Imunoglobulina G/análise , Infecções por Pasteurella/veterinária , Pasteurella multocida , Doenças das Aves Domésticas , Animais , Anticorpos Antibacterianos/análise , Anticorpos Antibacterianos/sangue , Galinhas , Esquemas de Imunização , Imunização Secundária , Imunoglobulina G/sangue , Infecções por Pasteurella/imunologia , Infecções por Pasteurella/prevenção & controle , Pasteurella multocida/imunologia
8.
Avian Pathol ; 22(1): 131-40, 1993 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-18671002

RESUMO

During August to October, 1983, 73 of 113 ducks submitted to our laboratory from a duck farm for pathological examination were found to have a variety of hepatic tumours. Grossly, the lesions could be divided into three groups: nodular, macro-nodular and diffuse forms; the nodular form was the most frequently seen (54/73). Histopathologically, the tumours could be classified into six categories: liver cell adenoma, cholangioadenoma, hepatocellular carcinoma, cholangiocarcinoma, mixed hepatic carcinomas and metastatic hepatic carcinoma, and the hepatocellular carcinoma was the most common (68/73).

9.
Vet Pathol ; 28(6): 519-23, 1991 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-1771742

RESUMO

To compare the effects of two inocula on the induction of amyloidosis in normal and thymectomized ducks, 180 normal and 50 thymectomized ducks were injected intravenously weekly for up to 16 weeks with either crude endotoxin or crude whole cell extract of a virulent strain of Escherichia coli (O78), and another 60 ducks were injected with normal saline as study control. During the first 5 weekly injections, the initial doses of inducing agents were the smallest and then adjusted upward to the maximum study doses (1 or 2 mg/bird of crude endotoxin and 15-18 x 10(8) bacteria/bird of crude whole cell extract), which were then maintained over the course of the study. The incidence of amyloid deposition were: 50.00% (25/50) for thymectomized ducks that received 1 mg/bird/week of crude endotoxin, 61.67% (37/60) for intact ducks that received 15 x 10(8)-18 x 10(8) bacteria (crude whole cell extract)/bird/week, 53.33% (32/60) for intact ducks received 2 mg/bird/week of crude endotoxin, and 63.33% (38/60) for intact ducks received 1 mg/bird/week of crude endotoxin. The results suggest that crude whole cell extract and crude endotoxin induced amyloidosis in ducks at similar rates and that, in ducks, thymectomy has no appreciable effect on the occurrence of amyloidosis.


Assuntos
Amiloidose/veterinária , Patos , Endotoxinas/toxicidade , Escherichia coli/fisiologia , Doenças das Aves Domésticas/microbiologia , Amiloidose/etiologia , Amiloidose/microbiologia , Animais , Infecções por Escherichia coli/complicações , Infecções por Escherichia coli/microbiologia , Infecções por Escherichia coli/veterinária , Enteropatias/etiologia , Enteropatias/microbiologia , Enteropatias/veterinária , Intestino Delgado/patologia , Fígado/patologia , Hepatopatias/etiologia , Hepatopatias/microbiologia , Hepatopatias/veterinária , Doenças das Aves Domésticas/etiologia , Baço/patologia , Esplenopatias/etiologia , Esplenopatias/microbiologia , Esplenopatias/veterinária
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...